Close Menu

NEW YORK (GenomeWeb) – Trovagene today announced it has signed an agreement to provide its Precision Cancer Monitoring tests and services to the national preferred provider organization FedMed.

Under the terms of the agreement, Trovagene will be covered as a participating laboratory testing provider for FedMed clients, which include major health insurers such as Aetna, Cigna and Humana. FedMed's network includes over 550,000 in-network physicians nationwide, the firm said in a statement.

Financial details of the agreement weren't disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Oct
31
Sponsored by
PerkinElmer

This webinar will provide an overview of how the Center for Applied Genomics at Children's Hospital of Philadelphia has optimized its next-generation sequencing (NGS) workflow using a combination of PerkinElmer's Sciclone automation technology and target capture chemistry from Twist Bioscience.